Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 20;22(1):73.
doi: 10.1186/s40644-022-00512-z.

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

E Lopci  1 , N Aide  2   3 , A Dimitrakopoulou-Strauss  4 , L Dercle  5 , A Iravani  6   7 , R D Seban  8   9 , C Sachpekidis  4 , O Humbert  10   11 , O Gheysens  12 , A W J M Glaudemans  13 , W A Weber  14 , A D Van den Abbeele  15 , R L Wahl  16 , A M Scott  17   18   19   20 , N Pandit-Taskar  21   22 , R J Hicks  23
Affiliations
Review

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

E Lopci et al. Cancer Imaging. .

Abstract

Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community and requires a multidisciplinary approach with involvement of oncologists, radiologists, and nuclear medicine specialists. There is evolving evidence that [18F]FDG PET/CT is a useful diagnostic modality for this purpose. The clinical indications for, and the principal aspects of its standardization in this context have been detailed in the recently published "Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0". These recommendations arose from a fruitful collaboration between international nuclear medicine societies and experts in cancer treatment. In this perspective, the key elements of the initiative are reported, summarizing the core aspects of the guidelines for radiologists and nuclear medicine physicians. Beyond the previous guidelines, this perspective adds further commentary on how this technology can advance development of novel therapeutic approaches and guide management of individual patients.

Keywords: Guideline; Immunotherapy; Malignant tumors, precision medicine; PET/CT; Positron emission tomography; Treatment response; [18F]FDG.

PubMed Disclaimer

Conflict of interest statement

E.L. reports receiving grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and from the Italian Ministry of Health and faculty remuneration from ESMIT (European School of Multimodality Imaging and Therapy) and MI&T congressi. R. J.H. is on the Scientific Advisory Board of Telix Pharmaceuticals with any honoraria donated to his institution, he is a stock holder in this company, and he is also an honorary Trustee of the International Cancer Imaging Society and honorary Board Member of Neuroendocrine Cancer Australia. W.A.W. has been on the advisory boards and receives compensation from Blue Earth Diagnostics. N.P. declares honoraria from Actinium Pharmaceuticals, AstraZeneca/MedImmune; Consulting or Advisory Role from Illumina, progenics; Speakers’ Bureau from Actinium Pharmaceuticals; Research Funding from Bayer Health; Bristol-Myers Squibb; Clarity Pharmaceuticals; Imaginab; Janssen; Regeneron; Travel, Accommodations Expenses from Bayer. The other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Timeline of [18F]FDG PET/CT interpretation during immunomodulatory treatment of solid tumors
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022. 10.1007/s00259-022-05780-2 Epub ahead of print. PMID: 35376991. - PMC - PubMed
    1. Lopci E. Immunotherapy monitoring with immune checkpoint inhibitors based on [18F]FDG PET/CT in metastatic melanomas and lung Cancer. J Clin Med. 2021;10(21):5160. doi: 10.3390/jcm10215160. - DOI - PMC - PubMed
    1. Aide N, Hicks RJ, Le Tourneau C, et al. FDG PET/CT for assessing tumour response to immunotherapy : report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–250. doi: 10.1007/s00259-018-4171-4. - DOI - PMC - PubMed
    1. Cho SY, Lipson EJ, Im HJ, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421–1428. doi: 10.2967/jnumed.116.188839. - DOI - PMC - PubMed
    1. Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–383. doi: 10.1007/s00259-017-3870-6. - DOI - PubMed

MeSH terms

Substances